Advancements in lung cancer diagnosis are transforming detection, making it earlier, more accurate, and less invasive, which is crucial for improving survival. Low-dose CT (LDCT) screening remains standard for high-risk individuals, identifying small lung nodules with minimal radiation exposure. Robotic-assisted bronchoscopy systems like MONARCH™ and Ion allow minimally invasive biopsies of previously inaccessible nodules, aided by mobile 3D CT imaging for real-time guidance. AI-powered analysis enhances radiologists’ ability to distinguish benign from malignant growths and prioritize high-risk lesions.
Liquid biopsies offer non-invasive monitoring by analyzing blood and sputum for circulating tumor cells, cell-free DNA, and other biomarkers. DNA methylation and emerging molecular markers improve differentiation of nodule types, while inhalable nanosensors detect cancer-related proteins and release signals detectable in urine, providing low-cost, accessible screening.
Complementing these, sputum cytology and breath analysis sensors identify volatile organic compounds associated with cancer, further enabling simple, non-invasive detection. Together, these innovations improve early diagnosis, reduce invasive procedures, and support personalized treatment planning.